Share on facebook
Share on twitter
Share on linkedin

December 3, 2014: BioAegis Therapeutics Closes Successful $8MM Convertible Note Round

Initial Funding Effort to Advance Recombinant Plasma Gelsolin Therapy into Human Trials

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that it has closed its final tranche of an $8MM convertible note round. These funds will be used to advance its clinical program into human clinical trials in severe community-acquired pneumonia.